Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.

Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.

Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.

Abstract: A powder inhaler includes: a housing having a port; a storage member located in the housing for storing a powder medicament; and a medicament-delivery member provided in the housing. The medicament-delivery member includes at least one concave portion for receiving medicament, and is capable of taking, relative to the storage member, a receiving position wherein the concave portion receives a predetermined amount of powder medicament from the storage member, and an inhalation position wherein the powder medicament can be inhaled through the admission port; and a stirring member for stirring the powder medicament stored in the storage member. An operation button is provided in the housing and is capable of moving between the initial position and a depressed position, while the operation button reciprocates between the initial position and the depressed position, the concave portion in the medicament-delivery member moves from the receiving position to the inhalation position and the stirring member operates.

Abstract: The subject invention provides a powder inhaler enabling the user to complete powder drug inhalation with fewer steps, for improved user convenience. A powder inhaler of the present invention comprises: a housing 1A having an admission port 2f on one end; a supplier having a drug-discharging hole, provided inside the housing 1A with a capacity sufficient to contain plural doses of a fine powder drug; a drug carrier having a measurement concave portion for receiving a single dose of a drug from the drug-discharging hole, the drug carrier being supported inside the housing 1A while being movable between a drug-receiving position for allowing drug supply from the drug-discharging hole to the measurement concave portion, and a drug-inhalation position for allowing drug inhalation from the measurement concave portion through the admission port; a cover cap C2 pivotably mounted to the housing 1A; and a vibrating means 60 brought into operation by pivoting the cover cap C2 so as to vibrate the supplier.

Abstract: A powder inhalator including: a housing, a supply member for holding a powdered drug for a large number of doses and having a drug discharge aperture at its bottom surface; a drug carrier, to which the powdered drug is supplied from the drug discharge aperture of the supply member, and having on its upper surface a measuring recess that has a volume equivalent to one dose of the drug; and an operation member disposed so as to move freely back and forth, and operate the drug carrier; the drug carrier moving in contact with the bottom surface of the supply member to carry the powdered drug loaded into the measuring recess from the position of the drug discharge aperture to an air inhalation channel, wherein the drug carrier is disposed slidably so that the measuring recess moves in a circular manner by sliding the drug carrier.

Abstract: An object of the present invention is to provide a powder inhaler that does not require shaking, and that therefore can be operated in an efficient manner.

Abstract: The present invention provides a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt and and a cyclodextrin.

Abstract: The subject invention provides a powder inhaler enabling the user to complete powder drug inhalation with fewer steps, for improved user convenience. A powder inhaler of the present invention comprises: a housing 1A having an admission port 2f on one end; a supplier having a drug-discharging hole, provided inside the housing 1A with a capacity sufficient to contain plural doses of a fine powder drug; a drug carrier having a measurement concave portion for receiving a single dose of a drug from the drug-discharging hole, the drug carrier being supported inside the housing 1A while being movable between a drug-receiving position for allowing drug supply from the drug-discharging hole to the measurement concave portion, and a drug-inhalation position for allowing drug inhalation from the measurement concave portion through the admission port; a cover cap C2 pivotably mounted to the housing 1A; and a vibrating means 60 brought into operation by pivoting the cover cap C2 so as to vibrate the supplier.

Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.

Abstract: A powder inhalator comprising: a housing; a supply member for holding a powdered drug for a large number of doses and having a drug discharge aperture at its bottom surface; a drug carrier, to which the powdered drug is supplied from the drug discharge aperture of the supply member, and having on its upper surface a measuring recess that has a volume equivalent to one dose of the drug; and an operation member disposed so as to move freely back and forth, and operate the drug carrier; the drug carrier moving in contact with the bottom surface of the supply member to carry the powdered drug loaded into the measuring recess from the position of the drug discharge aperture to an air inhalation channel, wherein the drug carrier is disposed slidably so that the measuring recess moves in a circular manner by sliding the drug carrier.

Abstract: The present invention provides a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt, and at least one polyoxyethylene-based nonionic surfactant selected from the group consisting of polyoxyethylene higher alkyl ethers and polyoxyethylene alkylphenyl ethers; a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt at a concentration of 0.05 to 0.5 W/V %, and an alcohol at a concentration of 20 to 80 W/V %, and not containing any surfactants; and a disinfectant and/or bactericidal aqueous composition containing an olanexidine acid addition salt, and at least one member selected from the group consisting of ester-based nonionic surfactants and cyclic oligosaccharides.

Abstract: A powder inhalator comprising: a housing; a supply member for holding a powdered drug for a large number of doses and having a drug discharge aperture at its bottom surface; a drug carrier, to which the powdered drug is supplied from the drug discharge aperture of the supply member, and having on its upper surface a measuring recess that has a volume equivalent to one dose of the drug; and an operation member disposed so as to move freely back and forth, and operate the drug carrier; the drug carrier moving in contact with the bottom surface of the supply member to carry the powdered drug loaded into the measuring recess from the position of the drug discharge aperture to an air inhalation channel, wherein the drug carrier is disposed slidably so that the measuring recess moves in a circular manner by sliding the drug carrier.